Cleveland inhaero novum research ostendit quod primum FDA-probatissimorum ibrutinib (ibrutinib) may quoque auxilium ad lymphoma facies leukemia et cerebrum tumores maxime communia et devorabunt, et erit in die cum aegris glioblastoma et amplio superessendam rates.
Secundum famam a American Association cerebrum tumor, et salvos glioblastoma rate est nimis, et media vexillum salvos aegris accepto curatio est minus quam XV mensibus. Glioblastoma mortiferum est omnium primaria est cerebrum tumore et repugnant optime vena treatments. Non opus est urgente providere aegris cum his treatments quam primum novae.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain similitudinem anorum in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
